BIOCODEX
17.1.2024 18:10:26 CET | Business Wire | Press release
Biocodex, a French pharmaceutical group with expertise in microbiota, women's health, orphan diseases, and My Health, a Belgian biotech company specializing in microbiota solutions, announce that they have signed a licensing agreement covering several countries in which the Biocodex Group operates, to market the DUOSPORE® dietary supplement.
My Health was founded in 2017 by Raf Dybajlo. In 2021, the company published a clinical study in The Lancet Gastroenterology & Hepatology on the efficacy of My Health’s proprietary strains, MY01 & MY02, in the treatment of functional dyspepsia (unexplained stomach complaints). The company has been marketing a range of probiotic food supplements whose formulas have been rigorously selected for their clinical efficacy, in response to growing consumer demand for solutions to digestive health, woman’s health, brain health, joint care and immune system boosting.
Through this licensing agreement, which is accompanied by the acquisition of a 20% minority stake in My Health, Biocodex intends to reinforce its leadership in microbiota and round out its range of probiotics, such as Ultra Levure® (commercialized in Belgium as Enterol®) and Alflorex®, widely known in France and around the world for the treatment of digestive disorders.
On the strength of its recognized expertise among healthcare professionals and its presence in over 100 countries worldwide, Biocodex hopes to make a success of this strategic partnership and significantly accelerate My Health international sales development.
Nicolas Coudurier, CEO of Biocodex, is delighted with the deal: "My Health and Biocodex share a common vision: we are convinced of the key role played by the microbiota in everyone's health and well-being, and believe that many ailments, particularly in the digestive sphere, can be treated by scientifically based probiotics such as those developed by My Health. I'm looking forward to supporting the development of a promising young company like My Health and continuing to play our part in raising awareness among the general public and healthcare professionals of the growing importance of the microbiota to our health and well-being."
Raf Dybajlo, CEO of My Health, expresses enthusiasm for the strategic partnership with Biocodex: “I’m honored that My Health’s innovative research and commercial success have been recognized by Biocodex. With our shared vision on the importance of microbiota solutions complemented by a joint dedication to innovation and science, we are excited to bring our solution for functional dyspepsia to many more countries, and with Biocodex as an expert in microbiota-targeted solutions, we found the perfect international partner to achieve this ambitious goal.”
About Biocodex
Biocodex, an independent, family-owned French pharmaceutical group founded in 1953, markets the probiotic strain Saccharomyces Boulardii CNCM I-745, a pioneer in the probiotic category and today No. 1 worldwide by value.
Biocodex is committed to improving the health and well-being of patients at every stage of their lives, focusing on three pillars: microbiota, women's health and orphan diseases. Its extensive product portfolio includes medicines, dietary supplements, medical devices and dermo-cosmetics.
The group has over 1,600 employees worldwide, 16 subsidiaries and is present in over 100 countries through its network of distributors; it generated sales of 501 million euros in 2022.
About My Health
My Health, an independent Belgian Biotech company, is a pioneer in advancing health through groundbreaking microbiome solutions. We are a first mover in the field of microbiome solutions for functional dyspepsia with DUOSPORE®, and have launched a diverse portfolio to effectively support people with various needs.
Our commitment is to bring innovative solutions and continue our development efforts. We work together with academic research labs in Belgium to develop new solutions for unmet needs as for example the treatment of Functional Dyspepsia and Recurrent Vulvovaginal Candidiasis (RVVC).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240117583860/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MariaDB Launches into the Agentic Era with an Agent-Ready Platform and a Bold New Brand4.11.2026 14:00:00 CET | Press release
MariaDB Enterprise Platform 2027 brings 56% higher throughput, more resilience and new AI capabilities to one durable foundation, and a new brand identity marks the company’s evolution from database to platform for the agentic enterprise MariaDB plc, the Unified Open Database Platform for the Agentic Enterprise, today announced MariaDB Enterprise Platform 2027, a release that delivers 56% higher peak throughput¹, stronger resilience for multi-region deployments and faster ways to build and run AI agents. What began as an open source operational database now spans mission-critical transactions, real-time analytics, in-memory speed, AI tooling and multi-region scale on one unified platform. The new brand identity unveiled alongside it shows where the company is headed, powering the AI-driven enterprise with the world’s most trusted database platform. Every AI agent in production is betting that the data in front of it is true. In most enterprises, that data is spread across multiple oper
Compass Pathways to Participate in Stifel 2026 Healthcare Conference on November 11th4.11.2026 12:30:00 CET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will attend the Stifel 2026 Healthcare Conference on November 11, 2026 and will participate in a fireside chat at 8:40am ET. A live audio webcast of the fireside chat will be accessible at the following link: https://event.summitcast.com/view/4aFtJriVa3BvDmNqmfSxma/k5kw3HNd3Rgm3cRza34muc A replay of the webcast will be accessible for 30 days following each event at the “Events” page of the Investors section of the Compass website. About Compass Pathways We believe mental health patients deserve the possibility of a better future. Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care. Our initial focus is developing COMP360 psilocybin, a proprietary, investigational, synthetic psilocybin treatment under evaluation for trea
Xsolla Expands DACH Presence With Xsolla Connect Berlin and Sponsorship of Games Ground Berlin4.11.2026 11:00:00 CET | Press release
Coordinated Activations Across Berlin Underscore Xsolla’s Continued Investment In The DACH Games Ecosystem, Bringing Developers, Publishers, Creators, And Partners Together Xsolla, a global video game commerce company that helps developers launch, grow, and monetize their games, today announces a comprehensive program of activations across Berlin throughout November 2026. As a main partner of Games Ground Berlin, Xsolla is supporting the festival’s Publisher Connect program and is hosting Xsolla Connect Berlin: Publisher & Content Creator Edition, bringing together developers, publishers, and creators to explore new opportunities for collaboration and growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103176221/en/ Graphic: Xsolla During Games Ground Berlin, Xsolla will host Xsolla Connect Berlin, bringing together 15 publishers and over 40 selected German content creators at Alte Münze on November 6 for curated netwo
Yamaha Motor to Exhibit All-New RW Series’ RW700 and RW350 at EICMA4.11.2026 10:00:00 CET | Press release
- Adventure Scooters Bringing New Enjoyment to Mobility - Yamaha Motor Co., Ltd. (TOKYO: 7272) announced today that it will exhibit its new RW700 and RW350 models at EICMA 2026 (International Two-Wheeler Exhibition), one of Europe's largest motorcycle shows, to be held in Milan, Italy, from November 3rd. “RW” is an all-new series of models for global markets developed as new adventure scooters to transform everyday mobility into an experience bringing more color to people's lifestyles. The RW Series aims to offer new mobility experiences that seamlessly connect everyday life with the extraordinary, opening up new possibilities and discoveries in people’s lives by letting them explore detours off familiar roads that lead them to new sights and Kando. In addition to providing comfort and ease of use for urban environments, the RW Series boasts features and performance that entice users to freely turn off familiar roads and head out toward new scenery and experiences. The styling features
ANS Cuts IT Alert Noise by 83% with LogicMonitor Edwin AI4.11.2026 09:30:00 CET | Press release
Early results also show 45% fewer observability cases and 44% faster incident resolution, giving ANS engineers more time to improve customer services LogicMonitor®, the AI-first platform for Autonomous IT, and ANS Group, a leading UK technology and managed services provider, today announced early results from ANS's deployment of Edwin AI, demonstrating how AI is helping reshape managed services by reducing routine operational work and creating more capacity for proactive customer value. Since deploying Edwin AI in August 2026, ANS has reduced alert noise by 83%, observability incident volumes by 45% and average incident resolution times by 44%, while reporting a 500% return on its incremental Edwin AI investment.* ANS has also consistently maintained SLA performance above 97%. By correlating related alerts, accelerating investigations and recommending next steps, Edwin AI is helping ANS shift engineering capacity from reactive incident management toward more proactive customer services
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom